Roxane Laboratories, Inc. has announced the approval of their Abbreviated New Drug Application for Protriptyline HCl Tablets, USP, 5mg and 10mg. The product is available in bottles of 100 tablets for immediate shipment to wholesalers and pharmacies nationwide.Roxane Laboratories’ Protriptyline HCl Tablets, USP are AB rated to VIVACTIL(R) (protriptyline HCl). Annual sales of VIVACTIL(R) (protriptyline HCl) Tablets are approximately $11.3 Million.Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
Related Articles Read More >

Pfizer’s revenue soared in the pandemic, but its stock valuation slipped relative to industry peers since 2000

FTC approves Amgen-Horizon merger

An interactive look at the drugs accounting for a fifth of Medicare’s spending
